INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

Efficient gene transfer and stable transgene expression are two key features required for effective human gene therapy for congenital as well as many acquired disorders. Adeno-associated virus (AAV)-derived vectors are promising candidates for gene therapy because of their ability to mediate highly efficient gene transfer into several clinically relevant nondividing cell types, including neurons (7, 21, 28) and muscle cells (9, 13, 15, 22, 42), without inducing pathogenic or inflammatory side effects. Long-term expression of transgenes after AAV vector transduction into these tissues has also been documented (13, 15, 28, 42). One possible mechanism of AAV transgene stability is integration into the genomes of the transduced cells.

AAV is a human parvovirus with a 4.7-kb DNA genome containing two open reading frames, which encode the viral regulatory (rep) and structural (cap) proteins under the control of the p5, p19, and p40 promoters (25). The wild-type AAV (wtAAV) is able to integrate site specifically into the human host genome, at a particular locus (AAVS1) in chromosome 19 (16, 20, 34). This specific integration feature of AAV is believed to be mediated through its inverted terminal repeat (ITR) and Rep68 or Rep78 protein (4, 11, 27, 38). Rep-containing AAV vectors retain this specific integration feature, as demonstrated by our group (40) and others (1, 35). However, the rep gene is undesirable for engineering AAV-transducing vectors, due to its strong inhibitory effects on gene expression and cell growth (2). Recently, several groups (8, 14, 30, 33) demonstrated that rep AAV vectors could also induce DNA integration in immortalized cell lines including 293 cells, although not in a site-specific fashion. However, there has been no fully convincing and direct evidence confirming the integration of AAV recombinants in nondividing cells. Our previous observation of a progressively increasing PCR-amplified transgene-specific signal in high-molecular-weight DNA samples from transduced human NT neurons was shadowed by the possibility of episomal replication and/or single-to-double-strand conversion of the AAV vector (7). Even recently reported Southern analysis data, claimed as evidence of AAV-mediated integration in nondividing human CD34⁺ hematopoietic progenitor cells (10) and mouse muscle cells (42), could not rule out possible contributions from undefined concatemers of episomal forms of the vectors. Furthermore, the requirement for large amounts of genomic DNA renders this technique problematic for addressing the integration issue in small samples of cells or tissues both in vitro and in vivo. In support of AAV vector integration in mouse muscle cells, Fisher et al. (9) recently reported other lines of evidence, including PCR detection of AAV vector persistence as head-to-tail concatemers, which are frequently found in the integrated stage. However, it is not clear whether episomal forms of AAV or its derivatives exist with this head-to-tail structure, and thus the possibility of episomal contamination again could not be absolutely excluded. PCR amplification with one primer targeting the chromosome 19 AAVS1 region is also not applicable, due to the fact that rep AAV vectors do not appear to integrate with the same site-specific pattern as the wild-type virus. Thus, none of the current methodologies is able to comprehensively characterize the frequency of integration or address the possibility of AAV-mediated rearrangement in the integration site (22) in nondividing populations, especially in an in vivo setting.

In seeking a reliable method to analyze AAV-mediated integration in neural tissues, an advanced Alu-PCR approach (24) attracted our attention. As the major family of short interspersed repeat DNAs in humans, Alu sequences are present at the level of 9 × 10⁵ copies per genome (26). They have been well characterized as 7SL RNA dimeric retropseudogenes, about 300 bp in length (36, 37). The high frequency of Alu sequences, appearing on average every 4 kb in the human genome, in combination with PCR techniques which can amplify long DNA fragments should in theory allow identification of any integrated exogenous DNA. One of the obvious advantages of an Alu-PCR technique is its ability to discriminate against episomal forms of AAV vectors by employing one primer specifically targeting the Alu sequences in the human genome. Furthermore, it has been shown that an Alu-equivalent sequence, B1, is present in the rodent genome at a similar frequency. Since the rodent is one of the most frequently used animal models for in vivo gene transfer studies, it is important to determine whether these AAV vectors, derived from a human virus, integrate into rodent tissues in vivo. We now report a successful methodology applying Alu-PCR and B1-PCR to identify rep AAV vector-mediated DNA integration in nondividing cells of human origin in vitro and rodent in vivo, respectively. Our findings demonstrate stable AAV vector integration occurring in several highly susceptible targets.

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

CMV-gal AAV vectors. Construction and packaging of a recombinant AAV (rAAV) plasmid, CMV-gal (previously named AAV-gal), have been described in detail previously (7). Briefly, semiconfluent 293 cells were infected with adenovirus type 5 (Ad5; provided by N. Muzyczka, University of Florida) and then cotransfected with 18 µg of CMV-gal vector plasmid and 6 µg of pAd8 helper plasmid (provided by R. J. Samulski, University of North Carolina), using a standard calcium phosphate precipitation method. Three days posttransfection, cells were harvested and subjected to four freeze-thaw cycles to release the cell-associated virions. Contaminating Ad5 was inactivated by heating to 56°C for 30 min, and any remaining plasmid DNA was removed by treatment with 25 U of RNase-free DNase per ml at 37°C for 30 min. In some experiments, these AAV preparations were further purified by two rounds of ultracentrifugation on a CsCl gradient (1.38 g/ml). Packaged CMV-gal viral stocks were titered by the infectious center assay, a modification of the method described by McLaughlin et al. (23). Briefly, 50,000 293 cells were infected with serially diluted AAV stocks (1:1 to 1:10⁵) together with wtAAV and Ad5, both at a multiplicity of infection (MOI) of 5. After 30 h, cells were resuspended in 25 mM EDTA-phosphate-buffered saline and then trapped on a nylon membrane by vacuum filtration. Total DNA was fixed and then hybridized with a specific ³²P-labeled -galactosidase probe. The numbers of labeled dots representing the number of infected cells containing the actively replicated CMV-gal were counted and plotted to determine the infectious units (IU) per ml. The titers of our packaged viral lysates were usually in the range of 10⁸ IU/ml.

Cells. 293 cells were maintained in Eagle's minimal essential medium containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (pen/strep). The method for preparing human NT neurons was described previously (39). Briefly, the precursor NT2 cells were treated with 10 µM retinoic acid for 4 to 5 weeks and then replated at low density (1:6). One to two days later, top layers containing differentiated cells were mechanically dislodged and replated in culture dishes precoated with 0.01% poly-D-lysine-1:20 Matrigel (Collaborative Research). Cells were cultured in Dulbecco modified Eagle essential medium-10% FBS-pen/strep plus mitotic inhibitors for 3 weeks. The enriched and terminally differentiated neurons were maintained in Opti-MEM 1-5% FBS-pen/strep. Human primary alveolar macrophages from bronchoalveolar lavages were cultured in RPMI 1640-10% FBS-pen/strep. Transduction was performed by incubating cells with packaged CMV-gal vector at an MOI of 5 in a limited amount of medium without serum for 90 min at 37°C. Cells were then cultured in appropriate media with serum for another week.

Animals. Adult male Sprague-Dawley rats (weighing 250 to 270 g; Harlan Sprague-Dawley, Inc., Indianapolis, Ind.) were maintained in well-ventilated rooms at 24°C, 50% relative humidity, and a 12-h/12-h daily light cycle. Purina Rat Chow and tap water were given ad libitum. Intracerebroventricular injection of AAV vectors was performed as previously described (29). Briefly, animals were anesthetized with pentobarbital (65 mg/kg of body weight intraperitoneally). Five microliters of CMV-gal vector (5 × 10⁸ IU/ml) or artificial cerebrospinal fluid was injected into the left lateral ventricle on the coordinates of A-P (1 mm behind the bregma), D-V (5 mm from the skull), and Lat (1.2 mm). Two weeks postinjection, animals were euthanized and their brain tissues were collected for DNA isolation.

Alu-PCR and Southern hybridization. High-molecular-weight DNA was extracted from cultured cells or brain tissues 1 to 2 weeks after CMV-gal transduction, using Puregene DNA isolation kits (Gentra Systems, Research Triangle Park, N.C.); 100-ng DNA samples were subjected to Alu- or B1-PCR.

View larger version (14K): [in this window] [in a new window]   FIG. 1.   Schematic of Alu-PCR. Human genomic DNA from CMV-gal-transduced cells was amplified by using the first set of primers: Alu5, an Alu-specific primer containing a tag; and C1, a CMV-specific primer. After an initial 10 cycles of PCR, the first set of primers was destroyed by uracil DNA glycosylase-induced nicks at dUTP (filled box). cTag5 (open box) represents a sequence complementary to the tag sequence on the newly synthesized strand. These PCR products were further amplified by using an internal primer, C2, for the CMV sequence plus TagA5, containing 16 nucleotides of Tag sequence and 6 nucleotides of Alu5 sequence. C3 was used as a specific CMV oligonucleotide probe for Southern hybridization. C4 and TagA5 were used to further amplify the above Alu-PCR products in order to obtain discrete bands for direct sequencing.

Nested PCR, cloning, and sequencing. One microliter of the above PCR products from CMV-gal-transduced cells was subjected to another run of touchdown PCR amplification using a nested CMV primer, C4 (AACCCAAGCTTGCGGAACTCCATATATGG [Fig. 1]), in combination with TagA5, both at 10 pmol. Ten microliters of the amplification product was gel fractionated, transferred to a membrane, and then hybridized with the C3 probe. The rest of the reaction was fractionated in a 0.8% agarose gel. To reduce the background of nonspecific genomic DNA and to enhance the amplification of signals, the CMV-specific bands were extracted and then subjected to another round of nested PCR using a pair of internal primers: A5N (AAAAAGAATTCAGTGTTTGCTGACGCCAA) and C5N (ACACCAAGCTTATATATGGGCTATGAACT). The addition of the EcoRI and HindIII sites in A5N and C5N, respectively, was to facilitate cloning of the PCR fragments into plasmids. These PCR products were gel fractionated. The most intense fragment was then extracted and cloned into pGEM11Z (Promega, Madison, Wis.). In other cases, the original Alu-PCR products were subjected to three rounds of nested PCR, and the end products were then cloned directly into the pCR 2.1 vector according to the manufacturer's instructions (Original TA Cloning kit; Invitrogen Co., Carlsbad, Calif.). Purified plasmid DNA containing the PCR fragment was then subjected to dideoxy-chain termination sequencing.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

Development of Alu-PCR to study AAV integration. As a first test of whether an Alu-PCR technique was applicable for investigation of AAV vector-mediated integration in human cells, we applied this method in human 293 cells, since AAV vector integration is already well documented by fluorescence in situ hybridization in this cell line (8). rAAV vector-mediated gene transfer into this cell type is highly efficient. The result of a typical CMV-gal transduction into 293 cells is shown in Fig. 2.

View larger version (124K): [in this window] [in a new window]   FIG. 2.   5-Bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal) histochemical staining of 293 cells 2 days after transduction with the CMV-gal vector at an MOI of 15.

View larger version (60K): [in this window] [in a new window]   FIG. 3.   Alu-PCR analysis on 293 cell samples. (a and b) Cells were either untreated or transduced with a crude preparation of CMV-gal. (a) Aliquots of 25 µl of PCR products were loaded in a 1% agarose gel containing ethidium bromide. Lane 1, control sample without a genomic DNA template; lanes 2 to 6, 100 ng of genomic DNA isolated 8 days after transduction of the CMV-gal vector into 293 cells; lanes 7 to 11, 100 ng DNA from control 293 cells; lanes 2 and 7, 10 pmol of Alu5 primer alone for the first 10 cycles; lanes 3 and 8, 10 pmol of C1 primer alone; lanes 1, 4, and 9, Alu5-C1 at 10 pmol: 10 pmol; lanes 5 and 10, Alu5-C1 at 100:10; lanes 6 and 11, Alu5-C1 at 10:100. (b) The gel shown in panel a subjected to Southern blot analysis. PCR-amplified products on a nylon membrane were hybridized with a 32P-end-labeled specific CMV oligonucleotide probe (C3). (c and d) Alu-PCR amplification from 100 ng of genomic DNA isolated 8 days after transduction with CsCl gradient-purified CMV-gal. (c) Aliquots of 25 µl of PCR products loaded in an agarose gel. Lane 1, Alu5-C1 at 10 pmol: 10 pmol; lane 2, C1 primer alone. (d) The gel shown in panel c subjected to Southern blot analysis.

View larger version (26K): [in this window] [in a new window]   FIG. 4.   Sequence of a vector-cellular junction identified by Alu-PCR from 293 cells transduced with the CMV-gal rAAV vector. (a) The vector portion of the junction includes the 5' end of the CMV IE promoter (open box) and some AAV sequences (underlined) containing a partial AAV ITR. The cellular sequence contains a fragment with 64% homology to a human DNA sequence on chromosome Xq26.1 (dashed box), which is flanked by unidentified sequences not present in the CMV-gal vector (unmarked). The actual sequence in the shaded box is shown in panel b. The arrows in panels a and b point to the site of the vector-cellular junction.

AAV vector integration in nondividing cells in vitro. The same Alu-PCR technique that we used successfully to detect AAV integration in 293 cells was applied next in several types of nondividing human cells. One of the cell types chosen was human NT neurons, because our group and others have noted dramatic gene transfer efficiencies mediated by AAV vectors into neuron populations, both in vitro and in vivo (7, 21, 28). Other reasons for selecting this particular cell system for in vitro integration studies included its human origin, our previous successes using this line (7), and the fact that it represents a highly pure population of nondividing cells exhibiting typical neuronal features (39). NT neurons at 4 weeks of age were transduced with the packaged CMV-gal vector at an MOI of 3. One week later, chromosomal DNA was isolated and subjected to Alu-PCR amplification using the Alu5 and C1 primers. About one-third of the resulting PCR products were gel fractionated and subjected to hybridization with the C3 probe labeled with ³²P. A smeared pattern of amplified products was visible in sample lanes from both untreated and transduced NT neurons (Fig. 5a). However, specific signals detected by the C3 probe were found only in the sample from the CMV-gal-transduced cells (Fig. 5b). Consistent with the results from our previous study on 293 cells, multiple bands (1.9, 1.4, 1.1, 0.9, 0.6, 0.4, and 0.3 kb) were found in the transduced NT neuronal samples.

View larger version (45K): [in this window] [in a new window]   FIG. 5.   Alu-PCR analysis using an Alu5 primer. (a) Aliquots of 33 µl of Alu-PCR products from 100 ng of genomic DNA were loaded on a 1% agarose gel containing ethidium bromide. Lane 1, control human NT neurons; lane 2, NT neurons transduced with CMV-gal for 7 days; lane 3, control human alveolar macrophages; lane 4, transduced alveolar macrophages. (b) The gel shown in panel a subjected to Southern blot analysis with a 32P-end-labeled specific CMV oligonucleotide probe (C3).

View larger version (22K): [in this window] [in a new window]   FIG. 6.   Sequence of a vector-cellular junction identified by Alu-PCR from human NT neurons transduced with the CMV-gal rAAV vector. (a) The vector portion of the junction includes the 5' end of the CMV IE promoter (open box) and some AAV sequences (underlined) containing a partial AAV ITR. The cellular sequence includes a fragment with 98% homology to a human DNA sequence on chromosome 9q34 (dashed underlined). The actual sequence in the shaded box is shown in panel b. The arrows in panels a and b point to the site of the vector-cellular junction.

View larger version (46K): [in this window] [in a new window]   FIG. 7.   Alu-PCR analysis using an Alu3 primer. (a) Aliquots of 33 µl of Alu-PCR products from 100 ng of genomic DNA were loaded on a 1% agarose gel containing ethidium bromide. Lane 1, control human NT neurons; lane 2, NT neurons transduced with CMV-gal for 7 days; lane 3, control human alveolar macrophages; lane 4, transduced alveolar macrophages. (b) The gel shown in panel a subjected to Southern blot analysis with a 32P-end-labeled specific CMV oligonucleotide probe (C3).

AAV vector integration in rat brain in vivo. Based on our success using Alu-PCR to detect integration of an AAV transgene cassette in nondividing human NT neurons, we applied an Alu-PCR equivalent, B1-PCR, to brain samples from rats exposed to the same CMV-gal AAV vector. Two weeks after injection of 5 µl of crude preparation of CMV-gal viral stock (5 × 10⁵ IU, titered by infectious center assay) into the left lateral ventricle, genomic DNA from different brain regions was isolated separately and subjected to CMV-B1-PCR analysis. B1-5 is a primer covering the 5' region of the B1 consensus sequence (5), and its 5' end is linked to the same tag sequence used in the Alu primer (Fig. 1). Both B1-5 and the CMV-specific primer C1 (Fig. 1) were used at 10 pmol for the first 10 cycles of PCR amplification. The rest of the procedures, including treatment with uracil DNA glycosylase, touchdown PCR, gel fractionation, and Southern blot hybridization with the CMV-specific oligonucleotide probe, were carried out just as performed in the above Alu-PCR studies. Smeared B1-PCR products were visible in samples from both control and vector-injected rats in all of the sampled brain regions, including the frontal cerebral cortex, cerebellum, striatum, hypothalamus, and brainstem (Fig. 8a). However, only the hypothalamic DNA sample from the CMV-gal-injected animal had specific signals (0.9, 0.7, and 0.5 kb) reactive with the CMV probe (Fig. 8b).

View larger version (52K): [in this window] [in a new window]   FIG. 8.   B1-PCR analysis of rat brain samples. (a) Aliquots of 30 µl of B1-PCR products from 100 ng of genomic DNA were loaded on a 1% agarose gel containing ethidium bromide. Lanes 1 to 5, brain samples from a rat 2 weeks after injection with artificial CSF; lanes 6 to 10, samples from a rat injected with 5 × 105 IU of a crude preparation of the CMV-gal AAV vector; lanes 1 and 6, cerebral cortex; lanes 2 and 7, cerebellum; lanes 3 and 8, striatum; lanes 4 and 9, brainstem; lanes 5 and 10, hypothalamus. (b) The gel shown in panel a subjected to Southern blot analysis with a 32P-end-labeled specific CMV oligonucleotide probe (C3). (c and d) Alu-PCR amplification from 100 ng of hypothalamic genomic DNA isolated 2 weeks after injection with the CsCl gradient-purified CMV-gal. (c) Aliquots of 40 µl of PCR products were loaded in an agarose gel. Lane 1, B1-5-C1 at 10 pmol: 10 pmol; lane 2, C1 primer alone. (d) The gel shown in panel c subjected to Southern blot analysis.

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

A PCR strategy targeting Alu sequences has been used previously to examine cellular sequences flanking integrated hepatitis B virus in human hepatoma cells (24). We have now successfully adapted an Alu-PCR approach and an equivalent B1-PCR technique to directly identify AAV vector-mediated integration in nondividing cells of either human or rat origin. The samples included a rapidly dividing human cell line, terminally differentiated nondividing human NT neurons, primary human lung alveolar macrophages, and rat brain tissues. Findings from the dividing cells were in good agreement with those of other groups (8, 12, 30, 33), including observations using the fluorescence in situ hybridization method to analyze metaphase spreads. The reliability of this Alu-PCR technique in combination with Southern hybridization was confirmed by our observations of consistent patterns of specific signals in repeated amplifications from the same DNA sample. Most importantly, the successful sequencing of vector-cellular junctions identified by this new technique will enable further examination of the integration events of rAAV vectors in primary, nondividing cells or tissues.

Multiple transgene-specific bands were detected from each type of cells or tissues exposed to the packaged CMV-gal vector. It is possible that two signals represent different amplified products targeting the same AAV integration locus but flanked by different nearby Alu sequences. However, the chances that all the specific bands in a given sample were derived from a single integration site are very slim. It is unlikely that Alu sequences reside in such a high frequency in the genome, e.g., seven copies within a 1.8-kb span in the case of the transduced NT neurons. In support of this view, although only a small number of amplified junctions were sequenced, no site duplications were noted. It also cannot be ruled out that some AAV integration sites are undetectable by this Alu-PCR method. These would include sites located either too far from an Alu sequence (26) or near a particular Alu element with a sequence too divergent from the consensus and therefore unable to anneal efficiently with the Alu primer. Nevertheless, the detection of relatively small numbers of specific bands suggests that rep AAV vector-mediated integration is not entirely random; otherwise, a greater smearing of specific signals might be expected in the amplified chromosomal DNA samples from the mixed cell populations. Alternatively, many integration sites may be present but accompanied by a significant degree of bias toward a few select sites. It is possible that the junctions amplified by Alu-PCR are drawn primarily from these most preferred sites. It is also noteworthy that neurons and alveolar macrophages represent cell types known to be highly susceptible to stable AAV-mediated gene transfer. The detection of integrated transgenes in these lineages cannot be assumed to be characteristic of every primary cell type following exposure to rAAV.

It is well known that Rep protein provided in trans is critical for wtAAV-mediated site-specific integration into human chromosome 19. Although the rep gene cassette is not encoded by the rAAV vectors used, there are two possible sources of Rep in the rAAV stocks. The first one is contamination by wtAAV-like particles in the rAAV preparation. Using an infectious center assay, we detected very low levels of wtAAV-like particles, 2 IU rather than the 10⁵ IU of rAAV, in our crude preparations of rAAV. This contamination was not introduced from the helper Ad5 viral stocks, since no positive signals were detected in assays using a rep-specific DNA probe in a cell sample treated with Ad5 alone (41a). Kube et al. (17) reported similar findings for studies using CsCl gradient-purified rAAV stocks and hypothesized that "wild-type AAV-like particles can be generated by recombination events involving the recombinant AAV plasmid and the AAV helper plasmid, pAAV/Ad, during production of recombinant AAV." A second potential source of Rep could be Rep proteins attached to rAAV virions. Recently, two groups have reported that functional Rep proteins are tightly associated with and even encapsidated within wtAAV and rAAV virions (17, 31, 32). The role of these associated proteins in rAAV-mediated nonspecific integration remains to be defined. However, our results from sequencing several amplified vector junctions support the view that the strong affinity of wtAAV for a small region of human chromosome 19 is not mimicked by the rAAV vectors used here.

One of the main issues to be addressed in our present in vivo study was whether this type of human viral vector could mediate transgene integration in a rodent species. In other studies using the CMV-gal vector, we have noted little or no transgene expression in brain regions following intraventricular injection of the vector. However, using an otherwise isogenic AAV vector, AVP-gal, in which the transgene is driven by a native neurohormone promoter, we have detected significant amounts of gene expression, principally in the hypothalamus, although with weaker staining in a few other brain regions (41). Recent studies by other groups (21, 28) have demonstrated stable AAV transduction for at least 3 months in the rat or mouse central nervous system (CNS) in vivo, yet little is known about the mechanism(s) underlying the stability of AAV vectors in neuronal tissues. AAV-mediated integration is one possibility. Another key issue was whether this Alu-PCR methodology would be sufficiently sensitive to detect integrated AAV transgenes in brain cells. This is a critical question, especially for the brain, into which only small amounts of vector may be injected. Restricted diffusion of AAV vectors in brain tissue may also limit the numbers of cells in any given brain region harboring an AAV vector.

We therefore developed B1-PCR, an Alu-PCR equivalent, to examine AAV vector integration in the rat brain. By using the CMV-gal vector, we were able to take advantage of the same basic methodology that we had established and optimized for human cells. Two weeks after injection of the packaged CMV-gal into the lateral ventricle, transgene-specific signals were detected in the high-molecular-weight DNA sample from the hypothalamus but not from other regions including the frontal cerebral cortex, cerebellum, striatum, and brainstem. This result was not surprising since intraventricularly injected AAV vectors can easily reach the hypothalamus, due to the close proximity of this structure to the ventricular system; thus, a considerable amount of virus was likely delivered into hypothalamic tissue compared to the other sampled regions. This finding was consistent with the pattern of vector expression detected in our earlier histochemical study using the AVP-gal vector. The results also support a previous report by McCown et al. (21), suggesting that low levels of expression from an AAV-delivered transgene in the brain were due to inactivation of the CMV IE promoter rather than to the absence of the gene cassette. Most importantly, our B1-PCR data indicate for the first time that a human AAV-derived vector can integrate into the genomes of brain cells in a rodent species and confirm the ability of the B1-PCR technique to detect limited integration signals in vivo.

Several features of Alu-PCR analysis would appear to render it more attractive for the study of AAV vector integration in nondividing cells than other methodologies such as Southern blot analysis (10, 42) or PCR amplification of AAV head-to-tail junctions (9). Alu-PCR directly targets the vector-cellular junction sequences, which is not possible with alternative methods, and therefore avoids the attendant problems in interpretation resulting from episomal contamination. In addition, the combination of nested PCR and sequencing provides a relatively simple way to further examine the integration sites of AAV vectors in vivo and to elucidate possible sequence rearrangements near the junction site in both cellular and vector regions. By targeting a transgene possessing an endogenous counterpart present at a low copy number, it should also be possible to determine the actual AAV integration frequency by using quantitative Alu-PCR to compare intensities between endogenous and exogenous signals.

As the only known mammalian virus which can integrate into the human genome at a specific site (18), AAV possesses uniquely attractive features for certain applications of gene therapy. The demonstration of vector integration in treated brain and neuronal cell samples provides strong encouragement for further development of the AAV system for application in the CNS. Further characterization of this event in rats should be beneficial to the broad usage of the rodent as an animal model for investigating AAV-mediated gene delivery into the CNS. The Alu-PCR method described here will be a useful tool for further dissecting the mechanisms underlying this integration and may provide insights into designing strategies for the next generation of AAV vectors for human gene therapy.